Ollin Biosciences
Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD
$330MSeries B
Role not disclosedActivity from announced rounds
Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD